Chordoma
5
Pipeline Programs
4
Companies
5
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
1
3
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Small Molecule
150%
Monoclonal Antibody
150%
+ 3 programs with unclassified modality
Competitive Landscape
4 companies ranked by most advanced pipeline stage
Bavarian NordicDenmark - Kvistgard
2 programs1
1
BN-Brachyury plus radiationPhase 21 trial
TAEK-VAC-HerByPhase 11 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Bristol Myers SquibbNivolumab
Bavarian NordicBN-Brachyury plus radiation
Boehringer IngelheimAfatinib
ImmunityBioAldoxorubicin Hydrochloride
Bavarian NordicTAEK-VAC-HerBy
Clinical Trials (5)
Total enrollment: 119 patients across 5 trials
Nivolumab and Relatlimab in Treating Participants With Advanced Chordoma
Start: Apr 2019Est. completion: Sep 202310 patients
Phase 2Completed
BN Brachyury and Radiation in Chordoma
Start: Oct 2018Est. completion: Jan 202229 patients
Phase 2Completed
Afatinib in Locally Advanced and Metastatic Chordoma
Start: Jun 2018Est. completion: Jan 202543 patients
Phase 2Completed
QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma.
Start: Aug 2018Est. completion: Dec 20210
Phase 1/2Withdrawn
TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing Cancer
Start: Aug 2020Est. completion: Dec 202437 patients
Phase 1Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
4 companies competing in this space